Celgene Corporation


Celgene Corporation (CELG) Provides Update on the Fusion Clinical Program

Celgene Corporation (NASDAQ:CELG) announced that the FDA has placed a partial clinical hold on five trials and a full clinical hold on one …

Biotech’s Sell-Side Roundup: Cowen’s Take on Gilead Sciences, Inc. (GILD) and Celgene Corporation (CELG)

Gilead Sciences, Inc. Cowen analyst Phil Nadeau is out with a research note on shares of Gilead Sciences, Inc.

Celgene Corporation (CELG) Announces Phase 2a Results from Oral CC-220 in Patients with Lupus

Celgene Corporation (NASDAQ:CELG) announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company’s investigational, oral immunomodulatory compound, at the Annual European …

Celgene Corporation and Acceleron Announce Completion of Target Enrollment in MEDALIST and BELIEVE Phase 3 Studies

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of …

Celgene Corporation (CELG) Shares Slip; Here’s Why

Celgene Corporation (NASDAQ:CELG) shares are down nearly 2% this morning, after the drug giant reported mixed first-quarter results. While Celgene reported an in-line Revlimid number, Otezla missed …

Stock Update (NASDAQ:CELG): Celgene Corporation Announces Positive Phase III Results in Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 …

Friday’s Biotech Insights: Celgene Corporation (CELG), Synergy Pharmaceuticals Inc (SGYP)

Oppenheimer analysts are chiming in with upbeat forecasts on two biotech players: Celgene Corporation (NASDAQ:CELG) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP). One analyst is out …

Company Update (NASDAQ:CELG): Celgene Corporation’s Celgene International Sàrl Gets Positive CHMP Opinion to Expand REVLIMID Indication as Monotherapy in Multiple Myeloma

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

BTIG Reiterates Buy on Celgene Corporation (CELG) Despite Weak International Revlimid Sales

In a research report released Thursday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …

Cantor Bullish on Celgene Corporation (CELG) After Raising Guidance; Sees 36% Upside

Cantor analyst Mara Goldstein came out today with a bullish note on shares of Celgene Corporation (NASDAQ:CELG), after the pharma giant pre-announced 2016 results …